Abstract
THE formation of new blood vessels (angiogenesis) is critical for the growth of tumours1–3 and is a dominant feature in various angiogenic diseases such as diabetic retinopathy, arthritis, haemangiomas and psoriasis4. Recognition of the potential therapeutic benefits of controlling pathological angiogenesis has led to a search for angiogenesis inhibitors. Here we report that 2-methoxyoestradiol, an endogenous oestrogen metabolite of previously unknown function, is a potent inhibitor of endothelial cell proliferation and migration as well as angiogenesis in vitro. Moreover, when administered orally in mice, it strongly inhibits the neovascularization of solid tumours and suppresses their growth. Unlike the angiostatic steroids of corticoid structure5, it does not require the co-administration of heparin or sulphated cyclodextrins for activity. Thus, 2-methoxyoestradiol is the first steroid to have high antiangiogenic activity by itself. Our results suggest that this compound may have therapeutic potential in cancer and other angiogenic diseases.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Folkman, J., Watson, K., Ingber, D. E. & Hanahan, D. Nature 339, 58–61 (1989).
Blood, C. H. & Zetter, B. R. Biochim. biophys. Acta Rev. Cancer 1032, 89–118 (1990).
Mahadevan, V. & Hart, I. R. Eur. J. Cancer 27, 679–680 (1991).
Klagsbrun, M. & Folkman, J. in Peptide Growth Factors and Their Receptors II (eds Sporn, M. B. & Roberts, A. B.) 549–586 (Springer, Berlin, 1990).
Crum, R., Szabo, S. & Folkman, J. Science 230, 1375–1378 (1985).
Fotsis, T. et al. Proc. natn. Acad. Sci. U.S.A. 90, 2690–2694 (1993).
Schweigerer, L. et al. Eur. J. clin. Invest. 22, 260–264 (1992).
Montesano, R., Vassalli, J.-D., Baird, A., Guillemin, R. & Orci, L. Proc. natn. Acad. Sci. U.S.A. 83, 7297–7301 (1986).
MacLusky, N. J., Barnea, E. R., Clark, C. R. & Naftolin F. Catechol Estrogens (eds Merriam G. R. & Lipsett, M. B.) 151–165 (Raven, New York, 1983).
Seegers, J. C. et al. J. Steroid Biochem. 32, 797–809 (1989).
White, C. W., Sondheimer, H. M., Crouch, E. C., Wilson H. & Fan, L. L. New Engl. J. Med. 320, 1197–1200 (1989).
Ezekowitz, A., Mulliken, J. & Folkman, J. Br. J. Haemat. 79 (suppl. 1), 67–68 (1991).
Takamiya, Y., Friedlander, R. M., Brem, H., Malick, A. & Martuza, R. L. J. Neurosurg. 78, 470–476 (1993).
Pepper, M. S., Ferrara, N., Orci, L. & Montesano, R. Biochem. biophys. Res. Commun. 189, 824–831 (1992).
D'Amato, R. J., Lin, C. M., Flynn, E., Folkman, J. & Hamel, E. Proc. natn. Acad. Sci. U.S.A. (in the press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fotsis, T., Zhang, Y., Pepper, M. et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368, 237–239 (1994). https://doi.org/10.1038/368237a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/368237a0
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.